Videos

A trio of practitioners react to the FDA advisory committee's 10-1 vote against recommending approval of brexpiprazole (Rexulti) adjunctive to sertraline for adults with PTSD.

"Just like moons and like suns, With the certainty of tides, Just like hopes springing high, Still I'll rise..."

Rebecca Barbee, PA-C, CAQ-Psych, shares insights ahead of the the FDA meeting discussing brexpiprazole for PTSD.

The climate crisis has worsened... What can psychiatry do to help?

Panelists discuss how 17-year-old patients challenges with inattention, anxiety, and executive dysfunction ahead of college highlight the importance of balancing pharmacologic and non-pharmacologic ADHD treatments while addressing concerns about stimulant use and medication diversion.

Panelists discuss how treatment adherence in ADHD patients is often impacted by forgetfulness and misconceptions, and how using tools like pill organizers can significantly improve consistency and outcomes.

Panelists discuss the importance of setting realistic expectations when initiating pitolisant for narcolepsy, emphasizing consistent daily use, gradual titration, and patient-centered measures of success, while accounting for external stressors, lifestyle factors, and the need for occupational accommodations to support long-term functional outcomes.

Panelists discuss how behavioral strategies—including structured sleep routines, scheduled naps, dietary adjustments, light therapy, and cognitive behavioral support—are essential components of comprehensive narcolepsy management, reinforcing that individualized, nonpharmacologic interventions can significantly improve daily function and long-term outcomes.

Clinicians explore the potential of xanomeline-trospium for schizophrenia, emphasizing cautious evaluation and management of side effects for optimal patient outcomes.

Discover groundbreaking schizophrenia treatments using the muscarinic pathway, offering efficacy without common side effects of traditional antipsychotics.

Gerald Maguire, MD, shares insights on agitation in Alzheimer disease at the Southern California Psychiatry Conference.

Dr Jonathan Meyer highlights effective VMAT 2 inhibitors for tardive dyskinesia treatment, emphasizing tailored approaches for improved patient outcomes.

Innovative approaches enhance understanding of tardive dyskinesia's impact on patients' lives, shifting focus from detection to functional well-being.

Clinician discusses the importance of maximizing medication doses and trial periods for effectively managing tardive dyskinesia at the Southern California Psychiatry Conference.

Maguire discussed the differential diagnosis of bipolar depression at the Southern California Psychiatry Conference.

Deb York, PMHNP-BC, sheds light on postpartum psychiatry at the conference.

The Chair of the Southern California Psychiatry Conference offers his favorite take home points on schizophrenia and M1-M4 agonists that can be found in the initial sessions.

"Fifteen seconds, thirty, a minute of silence, sweat weeps from the intern’s forehead..."

Are you ready for new reading recommendations related to psychiatry?

Panelists discuss how viloxazine fits into both pediatric and adult ADHD treatment plans, especially as a non-stimulant option for patients with complex cases or concerns about stimulant side effects, while emphasizing flexible dosing and caregiver involvement.

Panelists discuss how recent clinical studies on viloxazine in children and adolescents demonstrated early symptom improvement, dose-dependent efficacy, and tolerability, with the most benefit seen at 400 mg in those aged 11 and under.

Panelists discuss the clinical and practical advantages of pitolisant for patients with frequent cataplexy and concerns about controlled substances, highlighting its dual efficacy, favorable safety profile, and flexible dosing as key features that support a patient-centered, stigma-conscious approach to narcolepsy care.

Panelists discuss the importance of shared decision-making in narcolepsy care, emphasizing structured conversations that explore patient goals, treatment preferences, and concerns—while navigating practical barriers like insurance—so that therapy selection is personalized and collaborative, often requiring a multimodal approach for optimal outcomes.

“Keep, ancient lands, your storied pomp!” cries she With silent lips. “Give me your tired, your poor, Your huddled masses yearning to breathe free, The wretched refuse of your teeming shore.

H. Steven Moffic, MD, discusses social psychiatric connections to the Declaration of Independence with some psychiatric additions to life, liberty, and pursuit of happiness.

Sara Robinson, DNP, RN, PMHNP-BC, provides insight on considerations surrounding prescribing psychiatric medications for perinatal patients.

Panelists discuss the critical importance of early diagnosis and personalized treatment in narcolepsy, using a case study to illustrate how tailored therapy—considering patient preferences, comorbidities, and lifestyle factors—can improve engagement, safety, and long-term outcomes.

Panelists discuss the evolving treatment landscape for narcolepsy, highlighting the growing availability of personalized therapies, persistent challenges with diagnosis and access, and the importance of clinician advocacy and education to ensure timely, individualized care for patients.